CRC driver positive cells (containing either an ERBB2 L755S or a PIK3CA H1047R alteration, or both) were enriched for proliferation-associated gene sets: MYC Targets V1 and P53 Pathway; several signaling pathways, apoptosis, and several immune-related gene sets (Allograft Rejection, and Interferon Alpha & Gamma responses). Here, MYC is linked to colorectal carcinoma.